Intriguingly, when Ja18−/− mice bearing B16 melanoma tumors were treated with CpG, tumor growth was significantly reduced compared to CD1d−/− mice (deficient in type I and type II NKT cells) [222]. This evidence concerns the gene CD1D and neoplasm.